96 related articles for article (PubMed ID: 22488177)
1. Progression of double-hit lymphoma in the midst of R-hyper CVAD.
Munoz J; Vekaria M; Hanbali A; Janakiraman N
Am J Hematol; 2013 Jan; 88(1):87-8. PubMed ID: 22488177
[No Abstract] [Full Text] [Related]
2. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
3. High-dose therapy for follicular lymphoma revisited: not if, but when?
Lister TA
J Clin Oncol; 2003 Nov; 21(21):3894-6. PubMed ID: 14517186
[No Abstract] [Full Text] [Related]
4. [Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C regimen].
Nakazato T; Suzuki K; Mihara A; Sanada Y; Yoshida S; Kakimoto T
Rinsho Ketsueki; 2010 Feb; 51(2):148-52. PubMed ID: 20379108
[TBL] [Abstract][Full Text] [Related]
5. 'The sandwich sign' of mesenteric lymphoma.
Hokama A; Nakamoto M; Kinjo F; Fujita J
Eur J Haematol; 2006 Oct; 77(4):363-4. PubMed ID: 16856921
[No Abstract] [Full Text] [Related]
6. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
[TBL] [Abstract][Full Text] [Related]
7. CHOP chemotherapy followed by Rituximab consolidation as first line treatment in patients with follicular lymphoma. Long-term follow-up of a phase 2 trial.
Jäger G; Quehenberger F; Linkesch W; Neumeister P
Eur J Haematol; 2007 May; 78(5):453-5. PubMed ID: 17419745
[No Abstract] [Full Text] [Related]
8. Primary mediastinal large B-cell lymphoma.
Faris JE; LaCasce AS
Clin Adv Hematol Oncol; 2009 Feb; 7(2):125-33. PubMed ID: 19367254
[TBL] [Abstract][Full Text] [Related]
9. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].
Ogura M
Rinsho Ketsueki; 2006 Jun; 47(6):495-512. PubMed ID: 16862978
[No Abstract] [Full Text] [Related]
10. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
[TBL] [Abstract][Full Text] [Related]
11. The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function.
Seshadri T; Hourigan MJ; Wolf M; Mollee PN; Seymour JF
Leuk Res; 2006 Apr; 30(4):483-5. PubMed ID: 16171861
[TBL] [Abstract][Full Text] [Related]
12. Adding rituximab to cyclophosphamide, vincristine and prednisone increases time to treatment failure or progression in people with untreated stage III/IV follicular lymphoma.
Ghielmini M
Cancer Treat Rev; 2005 Dec; 31(8):644-7. PubMed ID: 16289339
[No Abstract] [Full Text] [Related]
13. [Systemic follicular lymphoma with cutaneous manifestations and exclusively cutaneous recurrence].
Palacios Abufón A; Acebo Mariñas E; Gardeazabal García J; García-Ruiz JC
Actas Dermosifiliogr; 2012 Apr; 103(3):253-5. PubMed ID: 22093542
[No Abstract] [Full Text] [Related]
14. Clinical and molecular complete remission of primary duodenal follicular lymphoma following treatment with rituximab and cyclophosphamide, vincristine and prednisone chemotherapy.
Falorio S; Angrilli F; Fioritoni G
Intern Med J; 2009 Oct; 39(10):706-7. PubMed ID: 19849763
[No Abstract] [Full Text] [Related]
15. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
16. Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma.
Bravo-Perez C; Pajares I; Muiña B; Escobar H; Amigo ML; Garcia-Malo MD; Garcia J; Rodriguez-Pinilla SM; Piris MA; Ortuño FJ
Ann Hematol; 2020 Feb; 99(2):391-393. PubMed ID: 31858188
[No Abstract] [Full Text] [Related]
17. [A rare thyroid tumor].
Tabareau F; Ragage F; Berger F; Berger N; Guterman R; Bruch JF
Ann Pathol; 2010 Apr; 30(2):148-50. PubMed ID: 20451076
[No Abstract] [Full Text] [Related]
18. Composite lymphoma arising in the parotid gland: a case report.
Urano M; Mizoguchi Y; Nishio T; Abe M; Kuroda M; Saito S; Sakurai K
Auris Nasus Larynx; 2004 Mar; 31(1):89-93. PubMed ID: 15041061
[TBL] [Abstract][Full Text] [Related]
19. Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
Gill S; Lane SW; Crawford J; Cull G; Joske D; Marlton P; Mollee PN; Prince HM; Seymour JF
Ann Hematol; 2008 Sep; 87(9):727-34. PubMed ID: 18401583
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
